Date: 2018-05-08
Type of information: Development agreement
Compound: proprietary tumour-specific antibodies for TCB’s CAR-T platform
Company: TC BioPharm (UK) Scotia Biologics (UK)
Therapeutic area: Cancer - Oncology - Infectious diseases
Type agreement: development
Action mechanism: monoclonal antibody/CAR-T cell therapy
Disease:
Details:
- • On May, 2018, TC BioPharm and Scotia Biologics announced that they have formed a strategic collaboration to co-develop novel proprietary tumour-specific antibodies for TCB’s CAR-T platform. Using Scotia’s technology the two companies will develop a range of cancer-targeting single-chain antibodies, each of which can be formulated to treat a specific type of cancer. Antibodies developed by Scotia will be incorporated into TCB’s therapeutic ImmuniCAR® product range.
- TCB and Scotia will initially co-develop single-chain antibodies against GD2, Her2 and PSMA which are expressed in neuroblastoma, breast and prostate cancer respectively. TCB will also explore use of CD4 to target both lymphoblastic leukemia and HIV. This therapeutic approach will provide product development opportunities for the Company to either commercialise in-house or collaborate with third-party pharma partners.
- TCB’s ImmuniCAR® platform is built on unique properties of modified gamma delta (??) T cells to selectively target cancer whilst leaving healthy cells untouched. TCB intends to use this novel platform to develop new CAR-T based immunotherapies, with the aim of treating a broad range of cancers and major viral disease.
- Based in Aberdeen, Scotia Biologics is an immuno-technology company that specialises in generating and developing antibodies and vaccines for clinical diagnostic and immuno-therapy applications on fee for service basis. Having previously developed therapeutic antibodies for third-party customers, Scotia has realigned commercial focus into immuno-oncology and treatment of cancer patients with TCB.
Financial terms:
Latest news:
Is general: Yes
